Patients who take phosphate binders may be at a 22% higher risk of death that those who take other non-calcium based treatments.
The management of chronic kidney disease-mineral bone disorder (CKD-MBD) is central to the care of patients with kidney disease.
In addition to reducing serum phosphorus levels to within the recommended range, ferric citrate increases iron stores.
In a study, PA21 was as efficacious as sevelamer carbonate, but patients taking PA21 had a lower pill burden and better adherence.
Researchers observed the association among individuals with serum phosphorus levels measured after fasting for 12 or more hours.
Use is associated with fewer hospitalizations versus sevelamer carbonate and calcium acetate.
In mice with and without CKD, phosphorus levels decreased by an average of 35% by 6 hours after injection with long-acting PTH.
Protein levels found to modify the effect of serum phosphorus with mortality in hemodialysis patients.
Researchers compared the novel iron-based phosphate binder with sevelamer.
In a study, nurses and technicians educated groups of hemodialysis patients about phosphate binders.
Researchers tested an intervention that included an educational fair, phosphorus group social, and staff education on phosphate binders.
Researchers observed reduced phosphorus levels in HD patients whose diet restricted intake of phosphorus additives.
Declines in serum phosphorus over time may improve survival.
Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism.
Calcium-based and non-calcium-based binder use were associated with similar death risks.
Levels declined significantly from 7.2 to 5.0 mg/dL, data show.
Vascular calcification contributes to increased cardiovascular risk in dialysis patients.